Analyst Price Targets — BMEA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| March 24, 2025 1:27 pm | — | Oppenheimer | $10.00 | $2.79 | TheFly | Biomea Fusion price target lowered to $10 from $50 at Oppenheimer |
| October 31, 2024 7:29 am | Joseph Catanzaro | Piper Sandler | $19.00 | $10.34 | TheFly | Biomea Fusion price target raised to $19 from $10 at Piper Sandler |
| October 30, 2024 4:44 am | Peter Lawson | Barclays | $11.00 | $12.06 | TheFly | Biomea Fusion price target raised to $11 from $9 at Barclays |
| October 22, 2024 6:58 am | Joseph Pantginis | H.C. Wainwright | $40.00 | $11.24 | StreetInsider | H.C. Wainwright Reiterates Buy Rating on Biomea Fusion Inc. (BMEA) |
| September 27, 2024 8:41 am | Joseph Catanzaro | Piper Sandler | $10.00 | $9.90 | StreetInsider | Piper Sandler Reiterates Overweight Rating on Biomea Fusion Inc. (BMEA) |
| June 7, 2024 8:34 am | Joseph Pantginis | H.C. Wainwright | $15.00 | $4.24 | TheFly | Biomea Fusion price target lowered to $15 from $50 at H.C. Wainwright |
| June 7, 2024 7:25 am | George Farmer | Scotiabank | $21.00 | $11.27 | StreetInsider | Biomea Fusion Inc. (BMEA) PT Lowered to $21 at Scotiabank |
| June 7, 2024 4:48 am | Peter Lawson | Barclays | $5.00 | $11.27 | TheFly | Biomea Fusion downgraded to Equal Weight from Overweight at Barclays |
| June 14, 2022 11:04 am | Joseph Pantginis | H.C. Wainwright | $16.00 | $8.50 | Pulse 2.0 | Biomea Fusion (BMEA) Stock Price: $16 Target And Buy Rating |
Latest News for BMEA
•Translational data presented at ADA demonstrate icovamenib's potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes • Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients…
•Translational data presented at ADA demonstrate icovamenib's potential to promote muscle preservation and fat reduction, supporting its broader therapeutic utility in obesity and diabetes, including as a complementary therapy alongside GLP-1 receptor agonists to enhance metabolic health outcomes • Clinical data presented at ADA from COVALENT-112 show improvements in HbA1c and C-peptide in type 1 diabetes patients…
Collaboration will Assess the Potential Impact of the Combination of Icovamenib and Semaglutide on Physical Function, Body Weight, Body Composition, Muscle Health and Metabolic Outcomes Late-Breaking Preclinical Findings at the American Diabetes Association Annual Meeting June 5-8 Highlighting Potential Mechanisms through which Icovamenib may Support Metabolic Health SAN CARLOS, Calif., June 03, 2026 (GLOBE…
SAN CARLOS, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today announced that management will participate in the following investor conferences: H.C.
SAN CARLOS, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or “Biomea Fusion” or “the Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity company, today reported its financial results for the first quarter ended March 31, 2026, and provided a business update.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for BMEA.
U.S. House Trading
No House trades found for BMEA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.